ANAB ANAPTYSBIO, INC - 10-Q - (2025-11-04)

Financial Performance (9M Ended 9/30/2025) Collaboration Revenue surged to $126.4M (up from $48.2M in 2024), driven by milestones, including a $50M non-cash event as Jemperli sales surpassed $750M. The 9-month Net Loss narrowed substantially to ($62.8M) from ($123.4M) in 2024. This improvement was achieved while operating expenses fell to $145.4M. Crucially, the third quarter reversed the trend, reporting Net Income of $15.1M (Basic EPS $0.54). This YTD loss is heavily impacted by $60.2M in non-cash interest expense related to prior royalty monetization agreements

...

Join thousands of investors who never miss important market updates

Join